« Back
Home /
IFN-λ1, Human

IFN-λ1, Human

Item no.	Z02742-1
Manufacturer	GenScript
Amount	1 mg
Quantity options	1 mg 20 ug
Category	Oncology Neuroscience Neuroinflammation Targets for Rodent Neurosciences Neural Adhesion Molecules By Cell Type Blastoma Carcinoma Hematology Leukemia Melanoma Peptides & Proteins Recombinant Proteins Cell Biology Cell Culture Cytokines Adenocarcinoma Cardiovascular Research Atherosclerosis
Type	Proteins
Format	Sterile Filtered White lyophilized (freeze-dried) powder.
Specific against	Human (Homo sapiens)
Purity	>97% by SDS-PAGE and HPLC analyses.
Sequence	PTSKPTTTGK GCHIGRFKSL SPQELASFKK ARDALEESLK LKNWSCSSPV, FPGNWDLRLL QVRERPVALE AELALTLKVL EAAAGPALED VLDQPLHTLH, HILSQLQACI QPQPTAGPRP RGRLHHWLHR LQEAPKKESA GCLEASVTFN, LFRLLTRDLK YVADGNLCLR TSTHPEST
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	protein/Z02742-IL-29, IL-28A, IL-28B, and IL-29, also named interferon-lambda2 (IFN-lambda2), IFN-lambda3, and IFN-lambda1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 Rbeta) and a novel IL-28 receptor alpha (IL-28 Ralpha, also known as IFN-lambdaR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.</td></tr><tr><th>M.W.</th><td colspan="7"> Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.</td></tr><tr><th>Purity</th><td colspan="7"> >97% by SDS-PAGE and HPLC analyses.</td></tr><tr><th>Endotoxin Level</th><td colspan="7"> Less than 0.2EU/ug of rHuIFN-lambda1 as determined by LAL method.</td></tr><tr><th>Specific Activity</th><td colspan="7"> Fully biologically active when compared to standard. The ED50 is determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is typically 1-5 ng/ml,corresponding to a specific activity of > 2.0×105 units/mg.</td></tr><tr><th>Storage</th><td colspan="7"> This lyophilized preparation is stable at 2-8 C, but should be kept at -20 C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 C to -70 C. Avoid repeated freeze/thaw cycles.</td></tr><tr><th>Formulation</th><td colspan="7"> Lyophilized from a 0.2um filtered concentrated, solution in 20mM PB, pH 7.4, 130mM NaCl.</td></tr><tr><th>Reconstitution</th><td colspan="7"> We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 C. Further dilutions should be made in appropriate buffered solutions.</td></tr><tr><th>Physical Appearance</th><td colspan="7"> Sterile Filtered White lyophilized (freeze-dried) powder.</td></tr><tr><th>Usage</th><td colspan="7"> This material is for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.</td></tr><tr><th>Sequence</th><td colspan="7"> PTSKPTTTGK GCHIGRFKSL SPQELASFKK ARDALEESLK LKNWSCSSPV, FPGNWDLRLL QVRERPVALE AELALTLKVL EAAAGPALED VLDQPLHTLH, HILSQLQACI QPQPTAGPRP RGRLHHWLHR LQEAPKKESA GCLEASVTFN, LFRLLTRDLK YVADGNLCLR TSTHPEST</td></tr>
Similar products	Interferon-lambda1
Shipping Condition	Cool pack
Available
Specificity	Fully biologically active when compared to standard. The ED50 is determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is typically 1-5 ng/ml,corresponding to a specific activity of > 2.0x105 units/mg.
Manufacturer - Category	Proteins
Country of Origin	USA
Shipping Temperature	4°C
Storage Conditions	-80°C
Molecular Weight	Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.
Product Line	Cytokines
Manufacturer - Specificity	Fully biologically active when compared to standard. The ED50 is determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is typically 1-5 ng/ml, corresponding to a specific activity of > 2.0x105 units/mg.
Description	IL-28A, IL-28B, and IL-29, also named interferon-lambda2 (IFN-lambda2), IFN-lambda3, and IFN-lambda1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 Rbeta) and a novel IL-28 receptor alpha (IL-28 Ralpha, also known as IFN-lambdaR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 C. Further dilutions should be made in appropriate buffered solutions.
Formulation	Lyophilized from a 0.2um filtered concentrated, solution in 20mM PB, pH 7.4, 130mM NaCl.
Endotoxin Level	Less than 0.2EU/ug of rHuIFN-lambda1 as determined by LAL method.
Usage	This material is for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Z02742-1-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Delivery expected until 9/11/2025

Express Delivery: Save 6 days

Compare

Add to wishlist

Get an offer